Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02505217 · ClinicalTrials.gov registry record
Novel Biomarkers of Thrombotic Risk
A clinical trial, sponsored by University of Vermont.
- Completed
- Registry status
- 200
- Enrollment target
NCT02505217 is a clinical trial that has completed, run by University of Vermont. The registered enrollment target is 200 participants.
The verdict
NCT02505217 has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
Treatment of patients who have had a heart attack with drugs that prevent formation of blood clots has been shown to reduce the patient's risk of subsequent cardiovascular events such as heart attack, stroke, and death. Because new drugs have increased treatment options, the development of tests that can guide treatment should improve treatment selection and further reduce the risk of cardiovascular events as well as bleeding. This study is designed to assess the value of new tests. It is a prospective study that will enroll patients who have had a heart attack. Blood will be taken during hospitalization for a heart attack (1 day after their heart attack) and a second time 6 months later during an ambulatory clinical visit. Investigators will perform biochemical tests on the blood that assess the likelihood of making blood clots. One tablespoon of blood will be taken at each time. Taking this amount of blood poses no risk to the participant. Investigators will ask the participant whether they have had bleeding or cardiovascular events during the initial evaluation, the ambulatory follow-up at 6 months, and during a telephone interview 1 year after enrollment. During their 1 year of participation, investigators will review medical records and record information in a manner that protects the identity of all participants. We hypothesize that the biochemical test results will be similar at baseline and 6 month follow-up and that these biochemical tests will identify patients at greater risk of cardiovascular events and bleeding. Treatment of participants will not be altered by their participation in this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02505217
The ClinicalTrials.gov registry entry for NCT02505217 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02505217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02505217 about?
NCT02505217 is a clinical study titled "Novel Biomarkers of Thrombotic Risk". Treatment of patients who have had a heart attack with drugs that prevent formation of blood clots has been shown to reduce the patient's risk of subsequent cardiovascular events such as heart attack, stroke, and death. Because new drugs have increased treatment options, the development of tests tha...
What is the current status of trial NCT02505217?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2015-07. Estimated completion is 2018-02-15.
Who is sponsoring clinical trial NCT02505217?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.